EMDT oxalate

CAS No. 263744-72-5

EMDT oxalate( —— )

Catalog No. M26195 CAS No. 263744-72-5

EMDT oxalate is a selective 5-HT6 agonist, and has antidepressant effects.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 114 Get Quote
5MG 161 Get Quote
10MG 203 Get Quote
25MG 448 Get Quote
50MG 653 Get Quote
100MG 888 Get Quote
500MG 1782 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    EMDT oxalate
  • Note
    Research use only, not for human use.
  • Brief Description
    EMDT oxalate is a selective 5-HT6 agonist, and has antidepressant effects.
  • Description
    EMDT oxalate is a selective 5-HT6 agonist, and has antidepressant effects.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Endocrinology/Hormones
  • Target
    5-HT Receptor
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    263744-72-5
  • Formula Weight
    246.354
  • Molecular Formula
    C15H22N2O
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    CCc1[nH]c2ccc(OC)cc2c1CCN(C)C
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Krishan Kumar et al.Gadoteridol. Analytical Profiles of Drug Substances and Excipients, Academic Press, Volume 24,1996,Pages 209-241,
molnova catalog
related products
  • Zacopride hydrochlor...

    Zacopride is a highly potent 5-HT3 receptor antagonist (Kd = 0.38 nM) and 5-HT4 receptor agonist (Ki = 373 nM). It also is a selective IK1 channel agonist.

  • Targocil

    Targocil is used as a bacteriostatic inhibitor of wall teichoic acid (WTA) biosynthesis which can inhibit the growth of methicillin-susceptible S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA) (MIC90s: 2 μg/ mL) for both MRSA and MSSA.

  • Cerlapirdine

    Cerlapirdine is a selective, potent, full antagonist of the 5-hydroxytryptamine 6 (5-HT6) receptor. Cerlapirdine is already in clinical development for the treatment of cognitive disorders related to Alzheimer's disease and schizophrenia. It works by acting as a selective 5-HT6 receptor antagonist.